PPBT PE Ratio & Valuation, Is PPBT Overvalued

Historical Valuation

Purple Biotech Ltd (PPBT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.66. The fair price of Purple Biotech Ltd (PPBT) is between NaN to NaN according to relative valuation method.

Relative Value

Fair Zone

NaN-NaN

Current Price：4.44

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Purple Biotech Ltd (PPBT) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Purple Biotech Ltd (PPBT) has a current Price-to-Book (P/B) ratio of 18.36. Compared to its 3-year average P/B ratio of 69.32, the current P/B ratio is approximately -73.52% higher. Relative to its 5-year average P/B ratio of 116.85, the current P/B ratio is about -84.29% higher. Purple Biotech Ltd (PPBT) has a Forward Free Cash Flow (FCF) yield of approximately -94.40%. Compared to its 3-year average FCF yield of -126.45%, the current FCF yield is approximately -25.35% lower. Relative to its 5-year average FCF yield of -84.70%, the current FCF yield is about 11.45% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PPBT competitors is 4.98, providing a benchmark for relative valuation. Purple Biotech Ltd Corp (PPBT.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PPBT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PPBT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PPBT currently overvalued or undervalued?

What is Purple Biotech Ltd (PPBT) fair value?

PPBT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Purple Biotech Ltd (PPBT) is between NaN to NaN according to relative valuation method.

How does PPBT's valuation metrics compare to the industry average?

The average P/S ratio for PPBT's competitors is 4.98, providing a benchmark for relative valuation. Purple Biotech Ltd Corp (PPBT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Purple Biotech Ltd (PPBT) as of Mar 10 2026?

As of Mar 10 2026, Purple Biotech Ltd (PPBT) has a P/B ratio of 18.36. This indicates that the market values PPBT at 18.36 times its book value.

What is the current FCF Yield for Purple Biotech Ltd (PPBT) as of Mar 10 2026?

As of Mar 10 2026, Purple Biotech Ltd (PPBT) has a FCF Yield of -94.40%. This means that for every dollar of Purple Biotech Ltd's market capitalization, the company generates -94.40 cents in free cash flow.

What is the current Forward P/E ratio for Purple Biotech Ltd (PPBT) as of Mar 10 2026?

As of Mar 10 2026, Purple Biotech Ltd (PPBT) has a Forward P/E ratio of -0.39. This means the market is willing to pay $-0.39 for every dollar of Purple Biotech Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Purple Biotech Ltd (PPBT) as of Mar 10 2026?

As of Mar 10 2026, Purple Biotech Ltd (PPBT) has a Forward P/S ratio of 0.00. This means the market is valuing PPBT at $0.00 for every dollar of expected revenue over the next 12 months.

PPBT Valuation